Isolere Bio, a Donaldson Life Sciences business

About

Isolere Bio, founded in 2017, is a biotechnology company that focuses on optimizing bioprocessing for advanced therapeutics. Acquired by Donaldson Company, Inc. in 2023, Isolere Bio enhances Donaldson's Life Sciences portfolio with innovative separation and filtration solutions. The company aims to accelerate therapeutic development, improve product quality, reduce waste, and enhance global accessibility to medicines and vaccines. Isolere Bio develops reagents and processes to streamline the manufacturing of biologics. Their flagship technology, IsoTag™ reagents, is designed for the purification and efficient manufacturing of biopharmaceuticals, particularly viral vectors for cell and gene therapies. This technology improves product quality and purity while reducing production timelines, making therapies more affordable and accessible. As part of Donaldson's Life Sciences division, Isolere Bio leverages a strong legacy in filtration solutions to deliver comprehensive biopharmaceutical manufacturing solutions.